Publications by authors named "Victoria Borja"
Article Synopsis
- The UK's first multi-centre study is exploring whether using circulating tumor DNA (ctDNA) to guide adjuvant chemotherapy decisions is just as effective as standard treatment for early-stage colorectal cancer patients without minimal residual disease (MRD).
- The study involves recruiting patients with high-risk stage II and III colorectal cancer, who will be randomly assigned to receive ctDNA-guided chemotherapy or standard chemotherapy to compare their 3-year disease-free survival rates.
- The research aims to potentially spare patients from unnecessary chemotherapy, reduce toxicity, and save costs for the National Health Service (NHS), while targeting a total of 1621 participants across about 50 UK centers over four years.
